title: Contrast medium nephrotoxicity after renal artery and coronary angioplasty.
abstract: BACKGROUND
  Renal dysfunction induced by iodinated contrast medium (CM) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty (PTRA).
  
  
  OBJECTIVE
  To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention (PCI).
  
  
  METHODS
  A total of 33 patients successfully treated with PTRA (PTRA group, mean age 70+/-12 years, 23 female, basal creatinine 1.46+/-0.79, range 0.7-4.9 mg/dl) were compared with 33 patients undergoing successful PCI (PCI group), matched for basal creatinine (1.44+/-0.6, range 0.7-3.4 mg/dl), gender, and age. In both groups postprocedural (48 h) serum creatinine was measured.
  
  
  RESULTS
  Postprocedural creatinine level decreased nonsignificantly in the PTRA group (1.46+/-0.8 vs. 1.34+/-0.5 mg/dl, P=NS) and increased significantly in the PCI group (1.44+/-0.6 vs. 1.57+/-0.7 mg/dl, P<0.02). Changes in serum creatinine after intervention (after-before) were significantly different between the PTRA and PCI groups (-0.12+/-0.5 vs. 0.13+/-0.3, P=0.014). This difference was not related to either a different clinical risk profile or to the volume of CM administered.
  
  
  CONCLUSIONS
  In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients. The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity.
authors.affiliation: CNR Institute of Clinical Physiology of Pisa, Italy. paolomar@ifc.cnr.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Marraccini
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Bianchi
authors.forename: Enza
authors.initials: E
authors.lastname: Fommei
authors.forename: Cataldo
authors.initials: C
authors.lastname: Palmieri
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ciriello
authors.forename: Marco
authors.initials: M
authors.lastname: Ciardetti
authors.forename: Alessandro
authors.initials: A
authors.lastname: Mazzarisi
authors.forename: Goran
authors.initials: G
authors.lastname: Djukic
authors.forename: Antonio
authors.initials: A
authors.lastname: L'Abbate
mesh_terms: D000368:Aged; D017130:Angioplasty; D015906:Angioplasty, Balloon, Coronary; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003287:Contrast Media / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004198:Disease Susceptibility; D005260:Female; D006801:Humans; D006978:Hypertension, Renovascular / Q000628:therapy*; D007479:Iopamidol / Q000009:adverse effects / Q000031:analogs & derivatives*; D007674:Kidney Diseases / Q000139:chemically induced*; D007677:Kidney Function Tests; D008297:Male; D012077:Renal Artery; D015607:Stents
chemical_list: D003287:Contrast Media; C057937:iomeprol; D003404:Creatinine; D007479:Iopamidol